Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $206.67 Consensus Target Price from Analysts

by · The Markets Daily

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) has earned an average recommendation of “Buy” from the eight ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $206.67.

A number of equities research analysts have issued reports on KRYS shares. Citigroup upped their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Chardan Capital reaffirmed a “buy” rating and issued a $212.00 target price on shares of Krystal Biotech in a report on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th. Finally, Stifel Nicolaus upped their price objective on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th.

Check Out Our Latest Report on Krystal Biotech

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Hedge funds and other institutional investors have recently modified their holdings of the business. Wilmington Savings Fund Society FSB purchased a new position in Krystal Biotech in the 3rd quarter valued at approximately $40,000. Values First Advisors Inc. bought a new position in shares of Krystal Biotech in the third quarter worth $53,000. Quest Partners LLC purchased a new position in shares of Krystal Biotech in the second quarter valued at $71,000. GAMMA Investing LLC raised its stake in shares of Krystal Biotech by 184.8% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the company’s stock valued at $78,000 after purchasing an additional 279 shares during the period. Finally, Huntington National Bank lifted its holdings in Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after purchasing an additional 283 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

KRYS stock opened at $159.75 on Wednesday. The business has a 50-day simple moving average of $175.76 and a two-hundred day simple moving average of $183.92. The company has a market capitalization of $4.59 billion, a P/E ratio of 90.25 and a beta of 0.85. Krystal Biotech has a 52-week low of $107.50 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the prior year, the company posted ($0.67) earnings per share. Krystal Biotech’s revenue was up 879.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Krystal Biotech will post 2.97 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

(Get Free Report

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Read More